<DOC>
	<DOCNO>NCT01251653</DOCNO>
	<brief_summary>To establish maximum tolerate dose ( MTD ) oral afatinib ( BIBW2992 ) give combination gemcitabine docetaxel patient relapse refractory tumor . To assess safety combination . To investigate PK characteristic docetaxel gemcitabine oral afatinib ( BIBW2992 ) test treatment schedule . To assess antitumor activity .</brief_summary>
	<brief_title>A Phase I Dose Escalation Trial Afatinib Plus Gemcitabine Plus Docetaxel</brief_title>
	<detailed_description />
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Inclusion criterion : 1. histologically cytologically confirm diagnosis advance metastatic relapsed refractory solid tumor . Exclusion criterion : 1 . Active brain metastasis 2 . Patients know preexist interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>